Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Avoiding iatrogenic harm and fragmented investigation

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Safety before utilisation control

A care plan designed to reduce repeated investigation must never block assessment of abnormal physiology, a new red flag, overdose, withdrawal, self-harm, abuse or a materially changed presentation.

Action: Assess the immediate problem through the relevant acute pathway, compare it with the documented baseline, communicate why escalation is needed, and update the coordinated plan after the episode so future clinicians can distinguish routine recurrence from urgent change.

Synopsis

Reduce harm from duplicated tests, incidental findings, polypharmacy and contradictory explanations while preserving access to appropriate investigation, urgent care and shared decisions for genuinely new clinical change.

  • Before ordering a test, define the clinical question and how a positive, negative or incidental result would alter management.
  • Review shared records and previous results to avoid duplication, while recognising that an old normal test does not exclude new disease.
  • Create a single problem list that distinguishes established disease, persistent symptom mechanisms, unresolved uncertainty and adverse treatment effects.
  • Nominate a coordinating clinician or team and specify what each specialist owns, preventing simultaneous unconnected plans.
  • Explain incidental findings explicitly: whether they are causal, require surveillance or need no further action.
  • Use scheduled review and a written safety-net to reduce crisis-driven testing without denying legitimate access to care.
  • Reconcile medicines across prescribers, identify duplicate or dependence-forming drugs and change one important variable at a time where feasible.
  • Shared decision making includes the option of no test or no treatment, discussed with benefits, harms, uncertainty and the person's goals.

Key red flags

Abnormal vital signs, focal neurology, acute confusion, collapse or a new objective deficit overrides any routine limited-investigation plan.

Progressive weight loss, fever, bleeding, mass, severe night symptoms or changed pain requires fresh presentation-specific assessment.

Overdose, intoxication, dangerous withdrawal, medication duplication or serious adverse reaction needs urgent medicines and medical review.

Suicidality, self-neglect, coercive control, exploitation or inability to care for dependants requires proportionate mental-health and safeguarding action.

Investigation priorities

01
Shared-record reviewFirst step

Locate previous results, images, specialist reasoning, medicine changes and unresolved recommendations before repeating assessment.

Management branches

Before a testMake investigation purposeful

A new investigation or referral is being considered for persistent or recurrent symptoms.

  1. Review the chronology, examination, prior results and the person's concern, then state the precise diagnosis or decision the test addresses.
  2. Discuss likely benefits, false positives, incidental findings, procedural burdens and the option of planned observation with a safety-net.
  3. Request the focused test only when the result can change care, and assign responsibility for explaining and acting on every outcome.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG197 shared decision makingBenefits, harms, alternatives, decision support and joint discussion of what matters to the person.
  • NICE NG56 multimorbidity recommendationsCoordination, treatment burden, medicines review and individualised management planning.
  • NICE NG193 chronic pain recommendationsPerson-centred assessment, uncertainty, review and avoiding harmful low-value medicine initiation.
  • NHS England persistent physical symptomsIntegrated physical and psychological care with jointly developed treatment planning.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom